Figure 3. Efficacy of treatment in each group on atherosclerotic plaque progression in apolipoprotein E (APOE)-deficient mice. A: Representativeimages of atherosclerotic plaques in the aorta in each group. B: The percentage of en face plaque area in normal control, model control, andgroups treated with intercellular cell adhesion molecule 1 (ICAM-1)-targeted microbubbles (MBi) with ultrasound-targeted microbubble delivery(UTMD), and ICAM1-targeted and Endostar-loaded therapeutic microbubbles (MBie) with UTMD. *Significantly different at p<0.05 comparedto the model group.
